Syntheses of novel myxopyronin B analogs as potential inhibitors of bacterial RNA polymerase.
Based upon observations from our initial findings, additional myxopyronin B analogs have been prepared and tested for in vitro inhibitory activity against DNA-dependent RNA polymerase and antibacterial activity against Escherichia coli and Staphylococcus aureus.
Lira
Ricardo
R
Anadys Pharmaceuticals, Inc., 3115 Merryfield Row, San Diego, CA 92121, USA.
Xiang
Alan X
AX
Doundoulakis
Thomas
T
Biller
William T
WT
Agrios
Konstantinos A
KA
Simonsen
Klaus B
KB
Webber
Stephen E
SE
Sisson
Wes
W
Aust
Robert M
RM
Shah
Amit M
AM
Showalter
Richard E
RE
Banh
Virginia N
VN
Steffy
Kevin R
KR
Appleman
James R
JR
D000900:Anti-Bacterial Agents / Q000138:chemical synthesis / Q000737:chemistry / Q000494:pharmacology; D012321:DNA-Directed RNA Polymerases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D004791:Enzyme Inhibitors / Q000138:chemical synthesis* / Q000737:chemistry / Q000494:pharmacology*; D004926:Escherichia coli / Q000187:drug effects / Q000201:enzymology; D020128:Inhibitory Concentration 50; D007783:Lactones / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D008745:Methylation; D015394:Molecular Structure; D013211:Staphylococcus aureus / Q000187:drug effects / Q000201:enzymology
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D007783:Lactones; C040323:myxopyronin B; D012321:DNA-Directed RNA Polymerases